Cargando…
IV and oral fosfomycin pharmacokinetics in neonates with suspected clinical sepsis
BACKGROUND: Fosfomycin has the potential to be re-purposed as part of a combination therapy to treat neonatal sepsis where resistance to current standard of care (SOC) is common. Limited data exist on neonatal fosfomycin pharmacokinetics and estimates of bioavailability and CSF/plasma ratio in this...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8212774/ https://www.ncbi.nlm.nih.gov/pubmed/33855449 http://dx.doi.org/10.1093/jac/dkab083 |
_version_ | 1783709703695499264 |
---|---|
author | Kane, Zoe Gastine, Silke Obiero, Christina Williams, Phoebe Murunga, Sheila Thitiri, Johnstone Ellis, Sally Correia, Erika Nyaoke, Borna Kipper, Karin van den Anker, John Sharland, Mike Berkley, James A Standing, Joseph F |
author_facet | Kane, Zoe Gastine, Silke Obiero, Christina Williams, Phoebe Murunga, Sheila Thitiri, Johnstone Ellis, Sally Correia, Erika Nyaoke, Borna Kipper, Karin van den Anker, John Sharland, Mike Berkley, James A Standing, Joseph F |
author_sort | Kane, Zoe |
collection | PubMed |
description | BACKGROUND: Fosfomycin has the potential to be re-purposed as part of a combination therapy to treat neonatal sepsis where resistance to current standard of care (SOC) is common. Limited data exist on neonatal fosfomycin pharmacokinetics and estimates of bioavailability and CSF/plasma ratio in this vulnerable population are lacking. OBJECTIVES: To generate data informing the appropriate dosing of IV and oral fosfomycin in neonates using a population pharmacokinetic analysis of plasma and CSF data. METHODS: The NeoFosfo study (NCT03453177) was a randomized trial that examined the safety and pharmacokinetics of fosfomycin comparing SOC versus SOC plus fosfomycin. Sixty-one neonates received fosfomycin (100 mg/kg IV q12h for 48 h) and then they converted to oral therapy at the same dose. Two plasma pharmacokinetic samples were taken following the first IV and oral doses, sample times were randomized to cover the whole pharmacokinetic profile and opportunistic CSF pharmacokinetic samples were collected. A population pharmacokinetic model was developed in NONMEM and simulations were performed. RESULTS: In total, 238 plasma and 15 CSF concentrations were collected. A two-compartment disposition model, with an additional CSF compartment and first-order absorption, best described the data. Bioavailability was estimated as 0.48 (95% CI = 0.347–0.775) and the CSF/plasma ratio as 0.32 (95% CI = 0.272–0.409). Allometric weight and postmenstrual age (PMA) scaling was applied; additional covariates included postnatal age (PNA) on clearance and CSF protein on CSF/plasma ratio. CONCLUSIONS: Through this analysis a population pharmacokinetic model has been developed that can be used alongside currently available pharmacodynamic targets to select a neonatal fosfomycin dose based on an infant’s PMA, PNA and weight. |
format | Online Article Text |
id | pubmed-8212774 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-82127742021-06-21 IV and oral fosfomycin pharmacokinetics in neonates with suspected clinical sepsis Kane, Zoe Gastine, Silke Obiero, Christina Williams, Phoebe Murunga, Sheila Thitiri, Johnstone Ellis, Sally Correia, Erika Nyaoke, Borna Kipper, Karin van den Anker, John Sharland, Mike Berkley, James A Standing, Joseph F J Antimicrob Chemother Original Research BACKGROUND: Fosfomycin has the potential to be re-purposed as part of a combination therapy to treat neonatal sepsis where resistance to current standard of care (SOC) is common. Limited data exist on neonatal fosfomycin pharmacokinetics and estimates of bioavailability and CSF/plasma ratio in this vulnerable population are lacking. OBJECTIVES: To generate data informing the appropriate dosing of IV and oral fosfomycin in neonates using a population pharmacokinetic analysis of plasma and CSF data. METHODS: The NeoFosfo study (NCT03453177) was a randomized trial that examined the safety and pharmacokinetics of fosfomycin comparing SOC versus SOC plus fosfomycin. Sixty-one neonates received fosfomycin (100 mg/kg IV q12h for 48 h) and then they converted to oral therapy at the same dose. Two plasma pharmacokinetic samples were taken following the first IV and oral doses, sample times were randomized to cover the whole pharmacokinetic profile and opportunistic CSF pharmacokinetic samples were collected. A population pharmacokinetic model was developed in NONMEM and simulations were performed. RESULTS: In total, 238 plasma and 15 CSF concentrations were collected. A two-compartment disposition model, with an additional CSF compartment and first-order absorption, best described the data. Bioavailability was estimated as 0.48 (95% CI = 0.347–0.775) and the CSF/plasma ratio as 0.32 (95% CI = 0.272–0.409). Allometric weight and postmenstrual age (PMA) scaling was applied; additional covariates included postnatal age (PNA) on clearance and CSF protein on CSF/plasma ratio. CONCLUSIONS: Through this analysis a population pharmacokinetic model has been developed that can be used alongside currently available pharmacodynamic targets to select a neonatal fosfomycin dose based on an infant’s PMA, PNA and weight. Oxford University Press 2021-04-14 /pmc/articles/PMC8212774/ /pubmed/33855449 http://dx.doi.org/10.1093/jac/dkab083 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Research Kane, Zoe Gastine, Silke Obiero, Christina Williams, Phoebe Murunga, Sheila Thitiri, Johnstone Ellis, Sally Correia, Erika Nyaoke, Borna Kipper, Karin van den Anker, John Sharland, Mike Berkley, James A Standing, Joseph F IV and oral fosfomycin pharmacokinetics in neonates with suspected clinical sepsis |
title | IV and oral fosfomycin pharmacokinetics in neonates with suspected clinical sepsis |
title_full | IV and oral fosfomycin pharmacokinetics in neonates with suspected clinical sepsis |
title_fullStr | IV and oral fosfomycin pharmacokinetics in neonates with suspected clinical sepsis |
title_full_unstemmed | IV and oral fosfomycin pharmacokinetics in neonates with suspected clinical sepsis |
title_short | IV and oral fosfomycin pharmacokinetics in neonates with suspected clinical sepsis |
title_sort | iv and oral fosfomycin pharmacokinetics in neonates with suspected clinical sepsis |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8212774/ https://www.ncbi.nlm.nih.gov/pubmed/33855449 http://dx.doi.org/10.1093/jac/dkab083 |
work_keys_str_mv | AT kanezoe ivandoralfosfomycinpharmacokineticsinneonateswithsuspectedclinicalsepsis AT gastinesilke ivandoralfosfomycinpharmacokineticsinneonateswithsuspectedclinicalsepsis AT obierochristina ivandoralfosfomycinpharmacokineticsinneonateswithsuspectedclinicalsepsis AT williamsphoebe ivandoralfosfomycinpharmacokineticsinneonateswithsuspectedclinicalsepsis AT murungasheila ivandoralfosfomycinpharmacokineticsinneonateswithsuspectedclinicalsepsis AT thitirijohnstone ivandoralfosfomycinpharmacokineticsinneonateswithsuspectedclinicalsepsis AT ellissally ivandoralfosfomycinpharmacokineticsinneonateswithsuspectedclinicalsepsis AT correiaerika ivandoralfosfomycinpharmacokineticsinneonateswithsuspectedclinicalsepsis AT nyaokeborna ivandoralfosfomycinpharmacokineticsinneonateswithsuspectedclinicalsepsis AT kipperkarin ivandoralfosfomycinpharmacokineticsinneonateswithsuspectedclinicalsepsis AT vandenankerjohn ivandoralfosfomycinpharmacokineticsinneonateswithsuspectedclinicalsepsis AT sharlandmike ivandoralfosfomycinpharmacokineticsinneonateswithsuspectedclinicalsepsis AT berkleyjamesa ivandoralfosfomycinpharmacokineticsinneonateswithsuspectedclinicalsepsis AT standingjosephf ivandoralfosfomycinpharmacokineticsinneonateswithsuspectedclinicalsepsis |